T-DXd作为G/GEJ癌的二线治疗有效

IF 81.1 1区医学 Q1 ONCOLOGY

Nature Reviews Clinical Oncology Pub Date : 2025-06-12 DOI:10.1038/s41571-025-01044-8

Peter Sidaway

{"title":"T-DXd作为G/GEJ癌的二线治疗有效","authors":"Peter Sidaway","doi":"10.1038/s41571-025-01044-8","DOIUrl":null,"url":null,"abstract":"Patients with HER2-positive (HER2+) metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with disease progression on first-line therapy have various treatment options available, although the most-effective agent remains uncertain. Now, data from the phase III DESTINY-Gastric04 trial confirm the superiority of trastuzumab deruxtecan (T-DXd) over ramucirumab plus paclitaxel in this setting.A total of 494 patients with disease progression on chemotherapy plus trastuzumab with or without an anti-PD-(L)1 antibody were randomized (1:1) to second-line therapy with T-DXd versus ramucirumab plus paclitaxel. Overall survival (OS) was the primary end point.","PeriodicalId":19079,"journal":{"name":"Nature Reviews Clinical Oncology","volume":"41 1","pages":""},"PeriodicalIF":81.1000,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"T-DXd effective as second-line therapy in G/GEJ cancers\",\"authors\":\"Peter Sidaway\",\"doi\":\"10.1038/s41571-025-01044-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Patients with HER2-positive (HER2+) metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with disease progression on first-line therapy have various treatment options available, although the most-effective agent remains uncertain. Now, data from the phase III DESTINY-Gastric04 trial confirm the superiority of trastuzumab deruxtecan (T-DXd) over ramucirumab plus paclitaxel in this setting.A total of 494 patients with disease progression on chemotherapy plus trastuzumab with or without an anti-PD-(L)1 antibody were randomized (1:1) to second-line therapy with T-DXd versus ramucirumab plus paclitaxel. Overall survival (OS) was the primary end point.\",\"PeriodicalId\":19079,\"journal\":{\"name\":\"Nature Reviews Clinical Oncology\",\"volume\":\"41 1\",\"pages\":\"\"},\"PeriodicalIF\":81.1000,\"publicationDate\":\"2025-06-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41571-025-01044-8\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41571-025-01044-8","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

HER2阳性（HER2+）转移性胃或胃食管交界处（G/GEJ）腺癌患者在一线治疗中病情进展有多种治疗选择，尽管最有效的药物仍不确定。现在，来自III期DESTINY-Gastric04试验的数据证实，在这种情况下，曲妥珠单抗德鲁西替康（T-DXd）优于拉穆单抗加紫杉醇。共有494名疾病进展的化疗加曲妥珠单抗伴或不伴抗pd -(L)1抗体的患者随机（1:1）接受T-DXd与拉穆单抗加紫杉醇的二线治疗。总生存期（OS）为主要终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

T-DXd effective as second-line therapy in G/GEJ cancers

Patients with HER2-positive (HER2⁺) metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with disease progression on first-line therapy have various treatment options available, although the most-effective agent remains uncertain. Now, data from the phase III DESTINY-Gastric04 trial confirm the superiority of trastuzumab deruxtecan (T-DXd) over ramucirumab plus paclitaxel in this setting.

A total of 494 patients with disease progression on chemotherapy plus trastuzumab with or without an anti-PD-(L)1 antibody were randomized (1:1) to second-line therapy with T-DXd versus ramucirumab plus paclitaxel. Overall survival (OS) was the primary end point.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature Reviews Clinical Oncology 医学-肿瘤学

CiteScore

99.40

自引率

0.40%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Nature Reviews publishes clinical content authored by internationally renowned clinical academics and researchers, catering to readers in the medical sciences at postgraduate levels and beyond. Although targeted at practicing doctors, researchers, and academics within specific specialties, the aim is to ensure accessibility for readers across various medical disciplines. The journal features in-depth Reviews offering authoritative and current information, contextualizing topics within the history and development of a field. Perspectives, News & Views articles, and the Research Highlights section provide topical discussions, opinions, and filtered primary research from diverse medical journals.